LATEST VERIFIED AI EXECUTION
Our quantitative model captured a massive +11.41% net profit on $TIP.MI in just 121h 17m. Stop guessing, start executing.
$IPN.PA
Ipsen SA
EUROPEAN UNIONLAST 10 EARNINGS GAPS (%)
QUANTITATIVE LIVE RADAR BLOTTER
Institutional execution stream for $IPN.PA
| Execution Date | Strategy & Setup | Direction | Execution Range | Hold Time | Exit Trigger | Net PnL |
|---|---|---|---|---|---|---|
| 2026-07-30 | QUANT ALGO | BUY x5 | $•••.•• → $•••.•• | 224m | 🔒 ENCRYPTED | -13.19% |
| ••••-••-•• | 🔒 LOCKED | ••• x• | $•••.•• → $•••.•• | ••h ••m | 🔒 LOCKED | +••.••% |
Exact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.
VOLATILITY & BIAS PROFILE
Intelligence Brief
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall… Read full dossier